Israeli pharmaceutical company Teva plans to extend its capacity by an investment of $100 million in Debrecen, Teva’s business development manager Péter Gábor said.
Teva is also considering its other plants in Poland, the Czech Republic and Ireland as potential investment sites, Gábor said. Teva will submit a bid to Hungarian Investment Promotion and Trade Development Kht (ITDH) to get government support for the plan, Gábor said. Teva Hungary Zrt produces drugs in Debrecen’s old Biogal plant, in Gödöllő’s old Human vaccine plant and in Sajóbábony, northeast Hungary. Teva purchased Biogal in 1995 and spent $520 million on investments in Hungary and $110 million for research and development in Hungary since then, Gábor said. The Sajóbábony plant cost Teva Ft 7 billion, while the Gödöllő plant Ft 2 billion. Teva reported non-consolidated Ft 32.5 billion net revenue in 2007, which is Ft 1.5 billion down on 2006. (Gazdasági Rádió)